Busadre, Joy D.
HRN: 01-18-25 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/03/2023
CLINDAMYCIN 300MG (CAP)
12/03/2023
12/10/2023
PO
300mg
TID
Invasive Breat Ca, Left, Infected
Waiting Final Action
Indication: Empirical De-escalation Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes